Infliximab

What is Infliximab?

Infliximab is a potent biologic medication, a type of monoclonal antibody, widely used in the treatment of several chronic autoimmune and inflammatory diseases. As a chimerical (mouse-human) IgG1 monoclonal antibody, it specifically targets and binds to tumor necrosis factor alpha (TNF-alpha), a key cytokine involved in inflammatory processes within the body. Administered intravenously, Infliximab works by neutralizing TNF-alpha, thereby reducing inflammation and modulating the immune response. It represents a significant advancement in managing conditions where excessive or uncontrolled inflammation plays a central role, offering relief and improved quality of life for many patients who have not responded adequately to conventional therapies.

How Does it Work?

The mechanism of action of Infliximab revolves around its ability to inhibit tumor necrosis factor alpha (TNF-alpha). TNF-alpha is a naturally occurring protein (cytokine) that acts as a pro-inflammatory mediator. In individuals with autoimmune diseases, TNF-alpha is often produced in excess, contributing to chronic inflammation and tissue damage. Infliximab works by binding to both soluble and transmembrane forms of human TNF-alpha, effectively neutralizing its biological activity. By blocking TNF-alpha, Infliximab prevents it from binding to its receptors and initiating the cascade of inflammatory responses. This inhibition leads to a significant reduction in inflammation, decreases the proliferation of inflammatory cells, and helps to restore immune balance. The result is a reduction in symptoms and progression of various inflammatory conditions.

Medical Uses

Infliximab is approved for the treatment of a range of chronic inflammatory and autoimmune conditions, typically when other treatments have proven ineffective or are not tolerated. Its broad application stems from its potent anti-inflammatory effects through TNF-alpha inhibition. Key medical uses include:

• Crohn's Disease: For moderate to severe active Crohn's disease in adults and children (6 years and older) who have not responded to conventional therapy, and for reducing fistulae in patients with fistulizing Crohn's disease.
• Ulcerative Colitis: For moderate to severe active ulcerative colitis in adults and children (6 years and older) who have had an inadequate response to conventional therapy.
• Rheumatoid Arthritis: In combination with methotrexate, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to methotrexate.
• Psoriatic Arthritis: For reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
• Ankylosing Spondylitis: For reducing signs and symptoms in adult patients with active ankylosing spondylitis.
• Plaque Psoriasis: For the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.

Dosage

The dosage and administration schedule for Infliximab vary depending on the specific condition being treated and the patient's weight. It is always administered as an intravenous infusion by a healthcare professional in a clinical setting. Typically, an initial induction phase involves infusions at week 0, week 2, and week 6. This is followed by a maintenance phase, where infusions are given approximately every 8 weeks. For example, in Crohn's disease and ulcerative colitis, a common starting dose is 5 mg/kg, while for rheumatoid arthritis, it's often 3 mg/kg, usually in combination with methotrexate. The infusion typically takes about 2-3 hours, and patients are monitored closely for any infusion-related reactions. Adjustments to the dose or frequency may be made based on the patient's response to treatment and tolerance.

Side Effects

While Infliximab can be highly effective, it is associated with potential side effects, some of which can be serious. Common side effects include infusion-related reactions (such as fever, chills, headache, rash, itching, or shortness of breath), infections (e.g., upper respiratory tract infections, urinary tract infections), nausea, abdominal pain, and fatigue. More serious side effects can occur due to its immunosuppressive nature. These include an increased risk of serious infections, including tuberculosis, fungal infections, and bacterial infections, some of which can be fatal. Patients should be screened for latent tuberculosis before starting treatment. Other serious risks include heart failure (new or worsening), liver problems, neurological disorders (e.g., multiple sclerosis-like syndrome), blood disorders, a lupus-like syndrome, and an increased risk of certain cancers, particularly lymphoma and skin cancer. It is crucial for patients to report any new or worsening symptoms to their healthcare provider immediately.

Drug Interactions

Due to its impact on the immune system, Infliximab can interact with other medications, potentially increasing the risk of side effects or reducing efficacy. Key drug interactions include:

• Live Vaccines: Administration of live vaccines (e.g., measles, mumps, rubella, varicella, yellow fever) is generally not recommended during Infliximab therapy due to the risk of infection in immunosuppressed patients.
• Other Biologic DMARDs or Immunosuppressants: Concurrent use of other biologic disease-modifying antirheumatic drugs (DMARDs) or potent immunosuppressants (like anakinra or abatacept) with Infliximab is generally avoided due to an increased risk of serious infections and neutropenia.
• Certain Drugs Affecting the Immune System: Caution should be exercised when Infliximab is used with other medications that suppress the immune system.
• Warfarin: While not a direct interaction, the inflammatory state can affect warfarin levels. As inflammation is reduced by Infliximab, warfarin dosages may need adjustment.

Patients should always inform their doctor about all medications, supplements, and herbal products they are taking before starting or during Infliximab treatment.

FAQ

Is Infliximab a form of chemotherapy?

No, Infliximab is not a chemotherapy drug. It is a biologic medication that works as an immunosuppressant by targeting TNF-alpha, a protein involved in inflammation. Chemotherapy drugs typically target rapidly dividing cells, including cancer cells.

How long does an Infliximab infusion typically take?

An Infliximab infusion usually takes approximately 2 to 3 hours. Patients are monitored during and after the infusion for any reactions.

Can I get vaccinated while on Infliximab?

Live vaccines are generally not recommended while taking Infliximab due to the increased risk of infection. Discuss your vaccination schedule with your doctor to determine which vaccines are safe for you.

What should I do if I miss an Infliximab dose?

If you miss a scheduled Infliximab infusion, contact your healthcare provider immediately to reschedule. It's important to stick to the prescribed schedule to maintain the medication's effectiveness.

Is Infliximab safe during pregnancy?

The use of Infliximab during pregnancy should be carefully discussed with a doctor. While animal studies have not shown direct harm, human data is limited. It is known to cross the placenta, especially in the third trimester. A risk-benefit assessment is essential.

Products containing Infliximab are available through trusted online pharmacies. You can browse Infliximab-based medications at ShipperVIP or Medicenter.

Summary

Infliximab is a pivotal TNF-alpha inhibitor that has revolutionized the treatment landscape for several chronic inflammatory and autoimmune diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By neutralizing the pro-inflammatory cytokine TNF-alpha, it effectively reduces inflammation and mitigates disease progression, offering significant symptomatic relief and improved quality of life for many patients. While highly effective, its use requires careful consideration of potential side effects, particularly the increased risk of serious infections and malignancies, and close monitoring by a healthcare professional. Understanding its mechanism, medical uses, proper dosage, and potential interactions is crucial for optimizing therapeutic outcomes and ensuring patient safety.